tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2020 Oct 13;7(11)
faa481.
doi: 10.1093/ofid/ofaa481. eCollection 2020 Nov.
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
Giuseppe Lapadula[SUP] 1 [/SUP], Davide Paolo Bernasconi[SUP] 2 [/SUP], Giacomo Bellani[SUP] 3 4 [/SUP], Alessandro Soria[SUP] 1 [/SUP], Roberto Rona[SUP] 3 [/SUP], Michela Bombino[SUP] 3 [/SUP], Leonello Avalli[SUP] 3 [/SUP], Egle Rondelli[SUP] 3 [/SUP], Barbara Cortinovis[SUP] 3 [/SUP], Enrico Colombo[SUP] 3 [/SUP], Maria Grazia Valsecchi[SUP] 2 [/SUP], Guglielmo Marco Migliorino[SUP] 1 [/SUP], Paolo Bonfanti[SUP] 1 4 [/SUP], Giuseppe Foti[SUP] 3 4 [/SUP], Remdesivir-Ria Study Group
Collaborators, Affiliations
Abstract
Background: Remdesivir has been associated with accelerated recovery of severe coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients requiring mechanical ventilation is uncertain.
Methods: All consecutive intensive care unit (ICU) patients requiring mechanical ventilation due to COVID-19 were enrolled. Univariate and multivariable Cox models were used to explore the possible association between in-hospital death or hospital discharge, considered competing-risk events, and baseline or treatment-related factors, including the use of remdesivir. The rate of extubation and the number of ventilator-free days were also calculated and compared between treatment groups.
Results: One hundred thirteen patients requiring mechanical ventilation were observed for a median of 31 days of follow-up; 32% died, 69% were extubated, and 66% were discharged alive from the hospital. Among 33 treated with remdesivir (RDV), lower mortality (15.2% vs 38.8%) and higher rates of extubation (88% vs 60%), ventilator-free days (median [interquartile range], 11 [0-16] vs 5 [0-14.5]), and hospital discharge (85% vs 59%) were observed. Using multivariable analysis, RDV was significantly associated with hospital discharge (hazard ratio
, 2.25; 95% CI, 1.27-3.97; P = .005) and with a nonsignificantly lower mortality (HR, 0.73; 95% CI, 0.26-2.1; P = .560). RDV was also independently associated with extubation (HR, 2.10; 95% CI, 1.19-3.73; P = .011), which was considered a competing risk to death in the ICU in an additional survival model.
Conclusions: In our cohort of mechanically ventilated patients, RDV was not associated with a significant reduction of mortality, but it was consistently associated with shorter duration of mechanical ventilation and higher probability of hospital discharge, independent of other risk factors.
Keywords: COVID-19; SARS-CoV-2; antiviral treatment; coronavirus; critically ill patients; intensive care unit; remdesivir.
. 2020 Oct 13;7(11)
faa481.doi: 10.1093/ofid/ofaa481. eCollection 2020 Nov.
Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
Giuseppe Lapadula[SUP] 1 [/SUP], Davide Paolo Bernasconi[SUP] 2 [/SUP], Giacomo Bellani[SUP] 3 4 [/SUP], Alessandro Soria[SUP] 1 [/SUP], Roberto Rona[SUP] 3 [/SUP], Michela Bombino[SUP] 3 [/SUP], Leonello Avalli[SUP] 3 [/SUP], Egle Rondelli[SUP] 3 [/SUP], Barbara Cortinovis[SUP] 3 [/SUP], Enrico Colombo[SUP] 3 [/SUP], Maria Grazia Valsecchi[SUP] 2 [/SUP], Guglielmo Marco Migliorino[SUP] 1 [/SUP], Paolo Bonfanti[SUP] 1 4 [/SUP], Giuseppe Foti[SUP] 3 4 [/SUP], Remdesivir-Ria Study Group
Collaborators, Affiliations
- PMID: 33204761
- PMCID: PMC7651598
- DOI: 10.1093/ofid/ofaa481
Abstract
Background: Remdesivir has been associated with accelerated recovery of severe coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients requiring mechanical ventilation is uncertain.
Methods: All consecutive intensive care unit (ICU) patients requiring mechanical ventilation due to COVID-19 were enrolled. Univariate and multivariable Cox models were used to explore the possible association between in-hospital death or hospital discharge, considered competing-risk events, and baseline or treatment-related factors, including the use of remdesivir. The rate of extubation and the number of ventilator-free days were also calculated and compared between treatment groups.
Results: One hundred thirteen patients requiring mechanical ventilation were observed for a median of 31 days of follow-up; 32% died, 69% were extubated, and 66% were discharged alive from the hospital. Among 33 treated with remdesivir (RDV), lower mortality (15.2% vs 38.8%) and higher rates of extubation (88% vs 60%), ventilator-free days (median [interquartile range], 11 [0-16] vs 5 [0-14.5]), and hospital discharge (85% vs 59%) were observed. Using multivariable analysis, RDV was significantly associated with hospital discharge (hazard ratio
, 2.25; 95% CI, 1.27-3.97; P = .005) and with a nonsignificantly lower mortality (HR, 0.73; 95% CI, 0.26-2.1; P = .560). RDV was also independently associated with extubation (HR, 2.10; 95% CI, 1.19-3.73; P = .011), which was considered a competing risk to death in the ICU in an additional survival model.
Conclusions: In our cohort of mechanically ventilated patients, RDV was not associated with a significant reduction of mortality, but it was consistently associated with shorter duration of mechanical ventilation and higher probability of hospital discharge, independent of other risk factors.
Keywords: COVID-19; SARS-CoV-2; antiviral treatment; coronavirus; critically ill patients; intensive care unit; remdesivir.